President and Interim Chief Executive Officer
Deborah Knobelman, Ph.D., was appointed President and Interim Chief Executive Officer of Kronos Bio in December 2024. She joined Kronos Bio in June 2024 as Chief Operating Officer and Chief Financial Officer, with responsibility for corporate strategy, investor relations, business development, communications, financial planning and analysis, and public company accounting functions.
Previously, as Chief Financial Officer & Head of Corporate Development at Senti Bio, Deb played a key role in taking the company public in 2022. During her tenure at Senti Bio, she oversaw investor relations, accounting, strategic finance, FP&A, facilities, legal, portfolio management, and corporate and business development.
Previously, Dr. Knobelman held interim C-suite positions at several life sciences companies, including Jogo Health, Thinklabs, and Aktiv Pharma Group. She also served as Chief Financial Officer at GeneriCo, LLC, and Chief Business Officer at Ampio Pharmaceuticals, Inc. Earlier in her career, she was Director of Commercial Strategy and Analytics at Pfizer Inc., and began her career as an equity research analyst covering specialty pharmaceuticals and biotech as a Senior Research Analyst for Piper Sandler Cos. (formerly Piper Jaffray), and as a Research Associate at JP Morgan & Co., Inc.
Known for her strategic acumen and ability to drive growth, Dr. Knobelman has successfully navigated complex financial landscapes and executed transformative business strategies. She holds an AB in Chemistry from Duke University and a Ph.D. in Pharmacology from the University of Pennsylvania School of Medicine.
Kronos Bio, Inc.
1300 So. El Camino Real
Suite 400
San Mateo, CA 94402
+1 (650) 781-5200
Kronos Bio, Inc.
301 Binney Street
2nd Floor East
Cambridge, MA 02142
© 2025 All rights reserved.